The above article [Her L and Zhu H-J (2020) Drug Metab Dispos, 48: 230-244; DOI: https://doi.org/10.1124/dmd.119.089680] was published with an error introduced by the compositor. In Table 1, the heading for the first column was incorrectly given as “ACE (Adrenocortical Extract) Inhibitors.” It should be “ACE (Angiotensin-Converting Enzyme) Inhibitors.” The corrected Table 1 is provided below.
TABLE 1.
List of CES1 substrates
| ACE (Adrenocortical Extract) Inhibitor | CNS (Central Nervous System) agents | Antihyperlidpidemia agents |
|---|---|---|
| Enalaprila | Methylphenidate | Clofibrate |
| Imidaprila | Cocaine | Fenofibrate |
| Benzaprila | Heroin | |
| Quinaprila | Mepridine | Adrenal glucocorticoid |
| Ramiprila | Flumazenil | Ciclesonidea |
| Trandolaprila | Rufinamide | |
| Antiviral agents | Anticancer agents | Chemical warfare agents |
| Oseltamivira | Capecitabinea | Sarin |
| Sofosbuvira | Irinotecana | Soman |
| Tenofovir alafenamidea | Telotristat etipratea | Tabun |
| Endogenous Compounds | Antiplatelets/anticoagulants | Pesticides |
| Cholesterol | Clopidogrel | Trans-permethrin |
| Fatty acid ethyl esters | Dabigatrana | Para-nitrophenyl valerate |
| Angiotensin receptor-neprilysin inhibitor (ARNi) | Immunosuppressive agents | Others |
| Sacubitrila | Mycophenolate mofetila | Dimethyl fumaratea |
| Oxybutynin |
a
Prodrugs that need CES1 activation.
The PDF and HTML versions of the article have been corrected.
The compositor apologizes for any inconvenience caused by this error.